Skip to main content
Targeting LRG-1 in oncology

Targeting LRG-1 in oncology

Normalisation of pathological neovascularisation in oncology
Profs Moss and Greenwood's technology has also demonstrated utility in normalising and improving the vascularisation of solid tumours, thus enabling better penetration - and thus improved efficacy - for small molecules (e.g. chemotherapy), biologics (e.g. checkpoint inhibitors) and cell therapies (e.g. CAR-T approaches). In partnership with UCLB, the team have built up a robust IP package and developed a proprietary fully-humanised monoclonal antibody. A UCLTF Licensing Project is underway to validate the performance of this technology versus standard of care in a range of relevant in vitro and in vivo models, as well as developing biomarkers and key assays for clinical application. Upon successful completion of this project, UCLTF will look to partner with other investors and pharmaceutical companies to rapidly progress the technology to clinic.